Original research article| Volume 75, ISSUE 3, P218-223, March 2007

Download started.


Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen



      Testosterone (T) gel, administered transdermally in combination with injections of depomedroxyprogesterone acetate (DMPA) every 3 months, results in effective suppression of spermatogenesis in 90% of men. Men's attitudes regarding the daily self-administration of T-gel and the impact of such a regimen on sexual function, however, are unknown. Therefore, we questioned subjects enrolled in a combination T-gel plus DMPA male contraceptive trial regarding the acceptability of T-gel for male contraception and the impact of the T-gel/DMPA regimen on sexual function and satisfaction during treatment.

      Study Design

      Thirty-eight healthy men, ages 18���55, were treated with T-gel (100 mg daily) + DMPA (300 mg every 3 months) for 24 weeks. Sexual function was assessed using a validated questionnaire at baseline, after 12 and 24 weeks of treatment and 12 weeks into recovery. The overall acceptability of the method and attitudes regarding the daily self-administration of T-gel were assessed by a questionnaire 12 weeks into recovery.


      Fifty percent of subjects were either satisfied or very satisfied with the T-gel-based contraceptive regimen, and 45% indicated they would use the regimen if it were commercially available. The T-gel was found to be easy to use by 76% of men, but a third of subjects felt that T-gel administration interfered with their daily routine. Sexual function was largely preserved during treatment; however, slight decreases in sexual function were noted during recovery.


      The experimental male hormonal contraceptive regimen of T-gel + DMPA is acceptable to approximately one half of study volunteers, most of whom would use the method if it were commercially available. Given its appeal to a significant proportion of men, additional studies using T-gel and DMPA for male contraception are warranted.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Amory J.K.
        • Page S.T.
        • Bremner W.J.
        Recent progress in male hormonal contraception.
        Nat Clin Prac Endocrinol Metab. 2006; 2: 32-41
        • Ringheim K.
        Evidence for the acceptability of an injectable hormonal method for men.
        Fam Plann Perspect. 1995; 27: 123-128
        • World Health Organization
        Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.
        Fertil Steril. 1996; 65: 821-829
        • Sjogren B.
        • Gottlieb C.
        Testosterone for male contraception during one year: attitudes, well-being and quality of sex life.
        Contraception. 2001; 64: 59-65
        • Zhang L.
        • Shah I.H.
        • Liu Y.
        • Vogelsong K.M.
        • Zhang L.
        The acceptability of an injectable once-a-month male contraceptive in China.
        Contraception. 2006; 73: 548-553
        • Meriggiola M.C.
        • Cerpolini S.
        • Bremner W.J.
        • et al.
        Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men.
        Hum Reprod. 2006; 21: 2033-2040
        • Buchter D.
        • Von Eckardstein S.
        • VonEckardstein A.
        • et al.
        Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception.
        J Clin Endocrinol Metab. 1999; 84: 1244-1249
        • Hair W.M.
        • Kitteridge K.
        • O'Conner D.B.
        • Wu F.C.
        A novel male contraceptive pill���patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men.
        J Clin Endocrinol Metab. 2001; 86: 5201-5209
        • Gonzalo I.T.
        • Swerdloff R.S.
        • Nelson A.L.
        • et al.
        Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
        J Clin Endocrinol Metab. 2002; 87: 3562-3572
        • Steidle C.
        • Schwartz S.
        • Jacoby K.
        • Sebree T.
        • Smith T.
        • Bachand R.
        North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.
        J Clin Endocrinol Metab. 2003; 88: 2673-2681
        • McNicholas T.A.
        • Dean J.D.
        • Mulder H.
        • Carnegie C.
        • Jones N.A.
        A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
        BJU Int. 2003; 91: 69-74
        • Page S.T.
        • Amory J.K.
        • Anawalt B.D.
        • et al.
        Testosterone gel combined with depomedroxyprogesterone acetate (DMPA) is an effective male hormonal contraceptive regimen and is not enhanced by the addition of the GnRH antagonist acyline.
        J Clin Endocrinol Metab. 2006; 91: 4374-4380
        • Kamischke A.
        • Venherm S.
        • Ploger D.
        • von Eckardstein S.
        • Nieschlag E.
        Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
        J Clin Endocrinol Metab. 2001; 86: 303-309
        • Turner L.
        • Conway A.J.
        • Jimenez M.
        • et al.
        Contraceptive efficacy of a depot progestin and androgen combination in men.
        J Clin Endocrinol Metab. 2003; 88: 4659-4667
        • Gu Y.Q.
        • Tong J.S.
        • Ma D.Z.
        • et al.
        Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men.
        J Clin Endocrinol Metab. 2004; 89: 2254-2262
        • Meriggiola M.C.
        • Constantino A.
        • Saad F.
        • et al.
        Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis and prostate.
        J Clin Endocrinol Metab. 2005; 90: 2005-2014
        • Herbst K.L.
        • Coviello A.D.
        • Page S.T.
        • Amory J.K.
        • Anawalt B.D.
        • Bremner W.J.
        Acyline, a gonadotropin releasing-hormone antagonist suppresses gonadotropins and testosterone for 15 days after a single dose.
        J Clin Endocrinol Metab. 2004; 89: 5959-5965
        • O'Leary M.P.
        • Fowler F.J.
        • Lenderkin W.R.
        • et al.
        Brief male sexual function inventory for urology.
        Urology. 1995; 46: 697-706
        • Panzer C.
        • Wise S.
        • Fantini G.
        • et al.
        Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction.
        J Sex Med. 2006; 3: 104-113
        • Heinemann K.
        • Saad F.
        • Wiesemses M.
        • et al.
        Attitudes toward male fertility control: results of a multinational survey on four continents.
        Hum Reprod. 2005; 20: 549-556
        • Glasier A.F.
        • Anakwe R.
        • Everington D.
        • et al.
        Would women trust their partners to use a male pill?.
        Hum Reprod. 2000; 15: 646-649